Skip to content

Perioperative Dezocine Administration and Postoperative Delirium in Elderly Cardiac Surgery Patients

Effect of Perioperative Dezocine Administration on Postoperative Delirium in Elderly Patients Undergoing Cardiopulmonary Bypass Cardiac Surgery: A Randomized Controlled Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07768150
Enrollment
640
Registered
2026-08-17
Start date
2026-09-01
Completion date
2028-01-01
Last updated
2026-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Delirium (POD)

Keywords

Dezocine, Postoperative delirium, Cardiopulmonary bypass, Cardiac surgery

Brief summary

Postoperative delirium (POD) is a common complication in elderly patients undergoing cardiac surgery and is associated with prolonged hospitalization, increased morbidity, and poor recovery. Currently, effective pharmacological strategies for preventing POD remain limited. This study aims to evaluate whether perioperative administration of dezocine can reduce the incidence of postoperative delirium in elderly patients undergoing cardiopulmonary bypass cardiac surgery. This is a prospective, randomized, controlled clinical trial conducted at Fuwai Hospital. Eligible patients aged 65 years or older undergoing elective cardiopulmonary bypass cardiac surgery will be randomly assigned to receive either dezocine or normal saline control in a 1:1 ratio. Patients in the dezocine group will receive intravenous dezocine (0.1 mg/kg) before anesthesia induction and again before transfer out of the operating room. At each administration time point, dezocine will be diluted with normal saline to a total volume of 6 mL and infused intravenously over 3 minutes. Patients in the control group will receive equivalent volumes of normal saline at the corresponding time points. The primary outcome is the incidence of postoperative delirium within 7 days after surgery. Secondary outcomes include delirium characteristics, postoperative recovery outcomes, pain scores, opioid consumption, sedation status, and perioperative complications. This study will investigate the potential role of dezocine as a preventive strategy for postoperative delirium in high-risk elderly cardiac surgery patients.

Interventions

Dezocine will be administered intravenously at a dose of 0.1 mg/kg before anesthesia induction and before transfer out of the operating room. At each administration time point, dezocine will be diluted with 0.9% normal saline to a total volume of 6 mL and infused over 3 minutes.

An equivalent volume of 0.9% normal saline will be administered intravenously at the same time points as the dezocine group, with the same infusion volume and administration procedure.

Sponsors

Chinese Academy of Medical Sciences, Fuwai Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≥65 years. 2. Patients scheduled for elective cardiac surgery requiring cardiopulmonary bypass. 3. Ability to complete preoperative cognitive assessment. 4. Written informed consent provided by the patient or legally authorized representative.

Exclusion criteria

1. Pre-existing neurological or psychiatric disorders that may affect postoperative delirium assessment, including dementia, active delirium, severe psychiatric disorders, recent stroke, or other severe neurological diseases. 2. Severe visual or hearing impairment or other conditions preventing postoperative delirium assessment. 3. Long-term use of opioid analgesics or sedative-hypnotic medications, or known allergy to dezocine. 4. Severe hepatic or renal dysfunction. 5. Emergency surgery, redo sternotomy, aortic surgery, or complex combined cardiac surgery.

Design outcomes

Primary

MeasureTime frame
Incidence of postoperative delirium within 7 days after surgeryWithin 7 days after surgery

Countries

China

Contacts

CONTACTKexin Liu
kexinliu0212@126.com+86 15316248964

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 18, 2026